Dolomite launches Educational Microfluidic Starter Kit
10 February 2015 | By kdm communications
Microfluidics specialist Dolomite has created a low cost kit aimed at educational initiatives or those new to microfluidics...
List view / Grid view
News
Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology
10 February 2015 | By Boehringer Ingelheim
Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement...
Hepatitis C: Doctors of the World opposes patent for sofosbuvir
10 February 2015 | By Doctors of the World
Doctors of the World - Médecins du Monde is today filing its opposition to the patent granted for sofosbuvir (Sovaldi) with the European Patent Office...
Statement on the rejection of abiraterone before chemotherapy by the Scottish Medicines Consortium
10 February 2015 | By The Institute of Cancer Research
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “We’re very disappointed that Scottish men with prostate cancer will miss out on the chance to have abiraterone much earlier in their course of treatment as a result of this decision..."
Pharmaceutical Licensing Group (PLG) announces the results of its 8th Annual Awards for excellence in business development
9 February 2015 | By Pharmaceutical Licensing Group
Pharmaceutical Licensing Group has announced the results of its 8th Annual Awards for excellence in business development which were given at its AGM on 5th February 2015...
Alkermes announces positive topline results from phase 1 study of ALKS 8700 for treatment of multiple sclerosis
9 February 2015 | By Alkermes plc
Alkermes plc announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis...
Lilly to present at Leerink Global Healthcare Conference
9 February 2015 | By Eli Lilly and Company
Eli Lilly and Company will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat at 8:25 a.m. EST...
Pfizer’s acquisition of Hospira lays foundation for potential generics unit spin-off, says GlobalData Analyst
9 February 2015 | By GlobalData
Adam Dion, MS, GlobalData’s Healthcare Industry Analyst, says: “On 5 February 2015, just days after gaining US Food and Drug Administration (FDA) breakthrough approval for Ibrance (palbociclib) in breast cancer, Pfizer entered into an agreement to purchase generic drug maker Hospira..."
FDA approves Roche’s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
Moberg Pharma extends distribution agreement with Menarini Group for Emtrix to Russia
9 February 2015 | By Moberg Pharma
Moberg Pharma AB announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine...
When I’m 64 – why the NHS could have to cope with one million more 50 plus people with serious illnesses in 10 years
9 February 2015 | By The International Longevity Centre
With demand for NHS services already under pressure, new analysis by the International Longevity Centre – UK and supported by Engage Mutual, the over-50s life cover specialists, predicts the NHS may have to support up to one million more older people with serious illnesses within the next ten years...
European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
Merck kicks off its Capacity Advancement Program (CAP) in collaboration with Emirates Diabetes Society (EDS) for the first time in United Arab Emirates
6 February 2015 | By Merck
The 5 year program was kicked off successfully in Africa, India and Indonesia and will further expand to other African and Asian countries in 2015...
Flu vaccine shows low effectiveness against the main circulating strain seen so far this season
6 February 2015 | By Public Health England
Flu vaccination remains important for other strains that still may circulate this winter...
Bristol-Myers Squibb to take part in Leerink Swann Global Health Care Conference
6 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will take part in the Leerink Swann Global Health Care Conference on Thursday, February 12, 2015, in New York...
